Chronic Radiation Ulcer
Conditions
Brief summary
The goal of this clinical trial is to learn if drug Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (PEP-TISSEEL) works to treat chronic radiation ulcer in adults and compare it with comparator TISSEEL. It will also learn about the safety of drug PEP-TISSEEL.
Interventions
COMBINATION_PRODUCTPEP-TISSEEL
Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
DRUGTISSEEL Fibrin Sealant KIT
Fibrin Sealant (TISSEEL® VH SD Kit)
Sponsors
Henry M. Jackson Foundation for the Advancement of Military Medicine
Walter Reed National Military Medical Center
Rion Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Phase 1 is open label, Phase 2 is controlled
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants in both study parts are eligible to be included if all of the following criteria apply: Age and Sex 1. Males and females aged ≥ 18 years at the time of signing the informed consent. Informed Consent 2. Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Type of Participant and Disease Characteristics 3. Status post-radiation treatment, with radiation-induced ulcer. This includes participants with moist desquamation as well as full epidermal necrosis and superficial dermal ulcerations (this wound would otherwise be allowed to heal by secondary intention). 4. Index ulcer classified as Grade 1 to Grade 3 according to the NCI-CTCAE, Version 5.0 5. Area of index ulcer must be between 1 and 15 cm2 at screening and at randomization/baseline. 6. Have failed conservative treatments including attempts at washing and local wound care, and be seeking therapy 7. The chronic radiation ulcers are limited to cutaneous (skin) ulcers and not impacting mucosal (oral, nose, etc.) tissue. Sex and Contraceptive/Barrier Requirements 8. Must meet one of the following criteria: a. Female participants of non-childbearing potential defined as : i. Postmenopausal for at least 1 year (participant verbal confirmation acceptable), or surgically sterilized (i.e., hysterectomy or bilateral oophorectomy more than 3 months prior to screening); or ii. Bilateral tubal ligation more than 6 months prior to screening; or iii. Must have a negative β-hCG blood pregnancy test at screening and not be breastfeeding prior to being administered with the IP b. Male participants of non-childbearing potential are defined as those vasectomized participants whose vasectomy was performed 6 months prior to screening or those diagnosed as sterile by a physician c. Females and males of childbearing potential who practice an acceptable method of contraception defined as the use of any form of hormonal contraceptive, a barrier method with spermicide, condoms, intrauterine device, or abstinence from sexual intercourse starting at least 60 days prior to screening and continuing at least 30 days following the last treatment. Female will undergo pregnancy tests and must have a negative β-hCG blood pregnancy test at screening visit and negative urine pregnancy test at baseline visit and must not be breastfeeding prior to being administered with the IP. Other Inclusion Criteria 9. Participants must be deemed by Radiation Oncologist at or greater than 6 months status/post-treatment to be without evidence of local recurrence 10. Ability to comply with the study protocol 11. Participants must be willing to undergo all clinical investigation-related procedures and attend all required visits including all follow-up visits
Exclusion criteria
Participants in both study parts are excluded if any of the following criteria apply: Medical Conditions 1. Study wound exhibits clinical signs and symptoms of infection at the screening visit 2. Any participant that has vascular compromise that is untreated as defined by as by defined abnormal invasive or non-invasive vascular studies 3. The index ulcer is within 2 cm of any other ulcer 4. The non-Cutaneous CRUs and ulcers impacting mucosal (oral, nose, etc.) tissue Liver Safety 5. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN) Prior/Concurrent Clinical Study Experience 6. Use of investigational drugs or biologics within 28 days prior to screening 7. Participation in another interventional clinical study in the past 30 days or concurrent participation in another interventional clinical study Diagnostic Assessments 8. Hemoglobin A1c (HbA1c) \> 8% 9. Serum creatinine l \> 2.5 mg/dL 10. Absolute neutrophil count of \<500 neutrophils per mm3 over the course of enrollment 11. Positive test for HBV, HCV, HIV Other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1(Phse1): Incidence of Treatment-Emergent Adverse Events (TEAEs) and Incidence of withdrawals from the study due to TEAEs | 20 week | — |
| Part 2 (Phase2): The proportion of participants with complete wound closure during the 20 weeks of the Treatment Phase | 20 weeks | Complete wound closure of the index ulcer is defined as 100% re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1(Phase1): The proportion of participants with complete wound closure during the 20 weeks of the Treatment Phase | 20 weeks | Complete wound closure of the index ulcer is defined as 100% re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart |
| Part 2(Phase2): Wound area change (%) during the 20 weeks of the Treatment Phase | 20 weeks | — |
| Part 2(Phase2): Time to complete wound closure during the 20 weeks of the Treatment Phase | 20 weeks | — |
| Part 2(Phase2):Incidence of Treatment-Emergent Adverse Events (TEAEs) | 20 weeks | — |
Countries
United States
Contacts
Primary ContactShariq Khan, M.S.
Backup ContactMaureen Maureen Merrifield, Ph.D.
Outcome results
None listed